Patients with inflammatory bowel diseases (IBD) frequently have extraintestinal manifestations including arthritis, sacroiliitis, and ankylosing spondylitis. While the treatment of these rheumatological conditions with traditional non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to lead to frequent IBD exacerbation, the safety of cyclooxygenase-2 (COX-2) inhibitors (Coxibs) remains unclear.
Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis
RIBALDONE, Davide Giuseppe;FAGOONEE, SHARMILA;DE ANGELIS, CLAUDIO GIOVANNI;SMEDILE, Antonina;CAVIGLIA, GIAN PAOLO;PELLICANO, Rinaldo
2015-01-01
Abstract
Patients with inflammatory bowel diseases (IBD) frequently have extraintestinal manifestations including arthritis, sacroiliitis, and ankylosing spondylitis. While the treatment of these rheumatological conditions with traditional non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to lead to frequent IBD exacerbation, the safety of cyclooxygenase-2 (COX-2) inhibitors (Coxibs) remains unclear.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2015;18;599-607.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
258.08 kB
Formato
Adobe PDF
|
258.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
